Key Stats for Thermo Fisher Stock
- Current Price: $622.18
- Target Price (Mid): ~$830
- Street Target: ~$631
- Potential Total Return: ~34%
- Annualized IRR: ~7% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Thermo Fisher Scientific (TMO) trades at $622.18, a whisker below its 52-week high of $647, after climbing about 23% over the past year. Right as the stock pressed toward that high, Chairman and CEO Marc Casper sold roughly 35,000 shares across August, joined by two senior deputies cashing out near $600 to $613.
The sales ran through pre-scheduled 10b5-1 plans, so they signal diversification more than any real-time verdict on price. Even so, they frame the question investors are asking: after a recovery that carried the stock off its May lows and back to the top of its range, at 33.5 times earnings, is there anything left for a buyer here?
What Changed Since the Rally, and What Management Signaled
The most concrete recent development was structural. On August 12, Thermo closed the sale of its microbiology business to private equity firm Astorg for roughly $1.075 billion, cash plus a $50 million seller note. On the July earnings call, this was still described as expected to close in the third quarter, so a pending deal is now done. It sharpens the portfolio toward higher-growth segments and, per CFO Jim Meyer, trims about $200 million from 2026 revenue net of retained channel sales.
The insider selling reads best against one line from that same call. Explaining why Thermo repurchased $1 billion of stock in Q2, Meyer said the company acted “based on an assessment of our valuation at that time.” Management found the shares attractive in the spring, near the low $500s. The stock is now roughly 20% higher, and executives are trimming personal stakes into that strength. None of it is bearish on its own because the sales were scheduled in advance. Together, though, they mark roughly where the obvious value has already been captured.
The Q2 print on July 23 was clean: revenue grew 10% to $11.99 billion, adjusted operating margin expanded 90 basis points to 22.8%, and adjusted EPS rose 13% to $6.03. Organic growth hit 5%, two points above guidance, and management raised the full year. Casper flagged the real shift plainly: “Definitely good momentum continues in pharma, but also biotech, clearly, we saw spending pick up.”
See historical and forward estimates for Thermo Fisher stock (It’s free!) >>>
A Full Multiple, But Not a Frothy One
At 33.5x trailing earnings and 20.8x NTM EV/EBITDA, TMO is not cheap against its own recent history, when it spent much of the past year in the high teens on that EBITDA multiple. It is not expensive compared to its best-quality peers either. IQVIA trades near 13.8x forward EV/EBITDA and Charles River near 15.7x, both below Thermo, but those are lower-margin services businesses. Against Waters at 19.4x and the differentiated bioproduction and instruments franchise Thermo actually owns, the premium is defensible. The multiple is full, which is precisely why the entry point now matters more than it did at $500.
See how Thermo Fisher performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $622.18
- Target Price (Mid): ~$830
- Potential Total Return: ~34%
- Annualized IRR: ~7% / year
See analysts’ growth forecasts and price targets for Thermo Fisher stock (It’s free!) >>>
TIKR’s mid-case model values Thermo Fisher at around $830 by the end of 2030, an implied total return of roughly 34%, or about 7% annualized. That is a respectable number for a franchise this durable, but a clear step down from the double-digit annualized returns the same model projected earlier this year, when the stock traded 20% lower. The re-rating did most of the work.
The revenue path leans on two drivers: recovering pharma and biotech spending, now converting from activity into orders, and the bioproduction franchise, where Casper says the DynaDrive single-use bioreactor “is quickly becoming the favorite technology” across contract manufacturers. Margin expansion is carried by the PPI Business System and volume leverage. The primary risk is academic and government demand, which Casper declined to call recovered: “We’re not calling yet that that’s the new level yet.”
The upside: end markets keep converting, and the model’s high case points toward roughly $1,240 by 2030. The downside: the P/E compresses harder than the model’s modest assumed contraction, thinning the return toward the low case near 3% a year.
Conclusion
The buy-here question resolves on one number: organic revenue growth on the next earnings call, Thermo’s third-quarter report this fall. Management guided the second half to about 4% organic, with Q3 and Q4 running similarly. Clear that bar, and the recovery reads as durable, and today’s full multiple gets easier to defend. Miss it, particularly if academic and government demand slips, and a stock priced for continued execution has room to fall. At $622, you are no longer buying the discount. You are paying for the recovery to keep going.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Thermo Fisher?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Thermo Fisher on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
